Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial

Vitiligo development in melanoma patients during immunotherapy is a favorable prognostic sign and indicates breakage of tolerance against melanocytic/melanoma antigens. We investigated a novel immunotherapeutic approach of the skin-depigmenting compound monobenzone synergizing with imiquimod in indu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Teulings, Hansje-Eva, Tjin, Esther P. M., Willemsen, Karina J., van der Kleij, Stephanie, ter Meulen, Sylvia, Kemp, E. Helen, Krebbers, Gabrielle, van Noesel, Carel J. M., Franken, Cornelis L. M. C., Drijfhout, Jan W., Melief, Cornelis J. M., Nieuweboer-Krobotova, Ludmila, Nieweg, Omgo E., van der Hage, Jos A., van der Veen, J. P. Wietze, Relyveld, Germaine N., Luiten, Rosalie M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889200/
https://ncbi.nlm.nih.gov/pubmed/29632737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1419113
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller